Metformin drug interactions
Pro Research Analysisby 
Searched over 200M research papers
Metformin Drug Interactions: Key Mechanisms and Clinical Implications
Metformin and Drug Transporter Interactions
Metformin relies on organic cation transporters (OCTs) and multidrug and toxin extruders (MATEs) for its absorption, distribution, and elimination. Many drug interactions with metformin occur when other medications inhibit these transporters, leading to increased plasma concentrations of metformin and a higher risk of metformin-associated lactic acidosis (MALA) . Notably, cimetidine, a common OCT and MATE inhibitor, can increase metformin exposure by inhibiting both hepatic OCT1 and, to a lesser extent, renal OCT2, resulting in higher systemic levels of metformin 348. These interactions are especially important in patients with impaired kidney function, as reduced renal clearance can further elevate metformin levels .
Metformin and Proton Pump Inhibitors (PPIs)
Proton pump inhibitors (PPIs) are frequently co-prescribed with metformin in patients with type 2 diabetes. While PPIs can inhibit organic cation transporters, clinical studies show that the impact on metformin’s pharmacokinetics is minimal, with only slight changes in metformin exposure (AUC changes ranging from -5.46% to +17%) and no significant effect on glycemic control (HbA1c levels) 59. However, some evidence suggests that long-term use of both PPIs and metformin may decrease vitamin B12 levels, so regular monitoring is recommended for high-risk patients . Among PPIs, esomeprazole appears to have the least interaction with metformin .
Metformin and Statins
Patients with type 2 diabetes often use both metformin and statins to manage cardiovascular risk. While both drugs affect glucose and lipid metabolism, current evidence suggests that their combination is generally safe, though careful monitoring is advised to avoid potential adverse effects from overlapping metabolic pathways .
Metformin and Natural Products
Natural supplements, such as goldenseal, can interact with metformin by affecting its absorption. Goldenseal was shown to decrease metformin exposure at lower doses, but this effect diminishes at higher metformin doses. Despite changes in metformin levels, no significant impact on glycemic control was observed, highlighting the importance of monitoring clinical biomarkers when assessing drug interactions with natural products .
General Considerations and Clinical Recommendations
Metformin is considered to have a low potential for drug interactions compared to other antidiabetic drugs. However, caution is warranted when it is used with medications that impair renal function or inhibit drug transporters, as these can increase the risk of adverse effects 126. Pharmacogenetic differences among individuals can also influence the magnitude of drug interactions with metformin, underscoring the need for personalized assessment in clinical practice 134.
Conclusion
Most clinically significant drug interactions with metformin involve inhibition of transporter proteins, especially in the kidney and liver. While interactions with PPIs and statins are generally minimal, caution is needed with drugs that impair renal function or inhibit OCTs and MATEs. Regular monitoring of glucose and vitamin B12 levels is recommended for patients on long-term metformin therapy, especially when combined with other medications. Personalized approaches considering pharmacogenetics and comorbidities can help optimize metformin therapy and minimize risks.
Sources and full results
Most relevant research papers on this topic
Drug Interactions of Metformin Involving Drug Transporter Proteins
Metformin drug interactions involve inhibition of Organic Cation Transporters and Multidrug and Toxin Extruders, leading to increased plasma metformin concentrations and increased risk of Metformin Associated Lactic Acidosis.
Quantitative Contributions of Hepatic and Renal Organic Cation Transporters to the Clinical Pharmacokinetic Cimetidine–Metformin Interaction
Cimetidine-metformin interaction primarily involves inhibition of hepatic OCT1 and minimally renal OCT2, with genetic variants of OCT1 and OCT2 moderately impacting the interaction.
Clinically and pharmacologically relevant interactions of antidiabetic drugs
Antidiabetic drug interactions are common, with metformin and saxagliptin showing low interaction potential, while incretin mimetics and SGLT-2 inhibitors have low interaction potential.
The Pharmacokinetic Interaction Between Metformin and the Natural Product Goldenseal Is Metformin Dose‐Dependent: A Three‐Arm Crossover Study in Adults With Type 2 Diabetes
Goldenseal's pharmacokinetic interaction with metformin is dose-dependent, with no clinically meaningful interaction observed in adults with type 2 diabetes.
Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drug-drug interactions.
Cimetidine's inhibition of OCT and MATE transporters in metformin kinetics can be accurately simulated using physiologically-based pharmacokinetic models, but requires incorporating complex electrochemical interactions and cimetidine concentrations.
DOI